BioSpace News Archive

As Canada’s Chief Public Health Officer, it is a priority for me that Canadians are equipped with accurate and evidence-based information in order to make well-informed decisions about their health.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, announced that it has entered into a share purchase agreement with institutional investors to purchase approximately $16.2 million of its common stock in a registered direct offering at a purchase price of $7.00 per share.

Senhwa Biosciences, Inc. announced their Abstract on Cholangiocarcinoma treatment with Silmitasertib has been accepted for oral/poster presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, 15-17 January, 2021.

In the wake of the novel coronavirus pandemic, the need for reliable, accurate, and accessible laboratory testing is more evident than ever before.

Artificial intelligence has the potential to revolutionize healthcare, but integrating AI-based techniques into routine medical practice has proven to be a significant challenge.

The opioid epidemic has only gotten worse since the advent of COVID-19, with some areas in the U.S. reporting a 50% increase in drug overdoses due to the pandemic.

Gannex, a wholly owned company of Ascletis Pharma Inc. and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced that it received Fast Track designation from the U.S. Food and Drug Administration for its non-alcoholic steatohepatitis drug candidate ASC42.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors.

A new study shows that a first-of-its-kind rapid test could identify which COVID-19 patients are responding to drug treatments and which patients are still deteriorating and need higher doses of medication.

During the all-virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo, leading scientific experts will dive into the groundbreaking advances that are the future of cancer care.